Precancerous Condition Clinical Trial
Official title:
Transcriptional Profiling of the Epidermal Response to Solar-Simulated Ultraviolet Radiation
RATIONALE: Testing of skin that has been exposed to artificial sunlight may help in
understanding the genetic processes involved in the development of skin cancer.
PURPOSE: This trial is studying the effect of solar-simulated ultraviolet radiation on skin
with or without sunscreen in healthy adults with skin that burns easily after only slight
tanning during sun exposure.
OBJECTIVES:
- Determine the global gene expression profiles in epidermal tissue of healthy
fair-skinned adults with Fitzpatrick skin type II after exposure to known doses of
solar-simulated ultraviolet radiation (ssUVR) (UVA).
- Determine the ability of an FDA-standardized sunscreen to alter ssUVR-induced
transcription profiles in vivo in these participants.
- Determine whether the transcriptional profiles of keratinocytes exposed to UVR in cell
culture are comparable to the profiles of keratinocytes in skin after similar levels of
UVR exposure.
OUTLINE: This is a pilot, dose-response study followed by an in vivo transcriptional
profiling study in 2 different groups.
- Pilot study (verification of ultraviolet radiation dose response): Participants are
initially exposed to solar-simulated ultraviolet radiation (ssUVR) (UVA) on the back to
determine the minimum erythema dose (MED). Between 22-24 hours after exposure,
participants undergo shave biopsy from each of the 9 UV exposure sites and 1 unexposed
skin site.
- Group 1 (determination of ssUVR and UVA in vivo transcriptional profiles): On day 1,
participants are initially exposed to ssUVR on the back to determine the MED. On day 2,
participants are exposed to ssUVR (3 sites) and UVA (3 sites) at the MED on the
buttocks. Between 22-24 hours after exposure (day 3), participants undergo shave biopsy
from each of the 6 UV exposure sites and 2 unexposed skin sites.
- Group 2 (determination of sunscreen-protected in vivo transcriptional profiles): On day
1, participants are initially exposed to ssUVR on the back to determine the MED. On day
2, participants are exposed to ssUVR on unprotected skin (3 sites) and
sunscreen-protected skin (3 sites) at the MED on the buttocks. Between 22-24 hours
after exposure (day 3), participants undergo shave biopsy from each of the 6 UV
exposure sites and 2 unexposed skin sites.
Biopsies from all participants are analyzed by microarray analysis. One of the unexposed
epidermal samples is used for primary keratinocyte culture.
PROJECTED ACCRUAL: A total of 6-56 participants (6 for the pilot study and 50 [25 per group]
for transcriptional profiling) will be accrued for this study within 2 months.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT00653146 -
The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia
|
N/A | |
Completed |
NCT00550589 -
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
|
Phase 2 | |
Terminated |
NCT00629577 -
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
|
Phase 1 | |
Completed |
NCT00103246 -
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT00066430 -
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
Phase 1 | |
Completed |
NCT00522197 -
ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia
|
Phase 2 | |
Completed |
NCT00003384 -
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer
|
N/A | |
Terminated |
NCT02574442 -
Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
|
||
Completed |
NCT00719563 -
American Ginseng in Treating Patients With Fatigue Caused by Cancer
|
Phase 3 | |
Terminated |
NCT00899951 -
Studying Fentanyl in Patients With Cancer
|
N/A | |
Completed |
NCT00873288 -
Activating Collaborative CIS Support Via Targeted Provider Mailing
|
N/A | |
Terminated |
NCT00611650 -
Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia
|
Phase 2 | |
Completed |
NCT00462813 -
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
|
Phase 3 | |
Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
Completed |
NCT00666731 -
Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
|
||
Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|
||
Completed |
NCT00685568 -
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
|
Phase 1 | |
Terminated |
NCT00942422 -
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
|
Phase 2 | |
Completed |
NCT00788164 -
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
|
Phase 1 |